KBL Merger Corp. IV KBLM Archives

FridayOct 23, 2020 3:07 pm

SPAC Merger Fires Boosters for 180 Life Sciences’ Exploration in Unmet Medical Needs of Anti-inflammatories Space

Biotechnology company 180 Life Sciences has launched a variety of advanced clinical and preclinical-stage efforts to develop novel anti-inflammatory treatments for patients with chronic illnesses A planned merger with 180 Life Sciences advanced under a special purpose acquisition corporation (SPAC) is expected to be completed within the next month, resulting in a Nasdaq filing under the ticker ATNF 180 Life Sciences’s founders are an experienced team of medical scientists who pioneered anti-inflammatory pharmaceuticals in the 1990s that are still in use today, generating billions in revenue The company’s own-IP clinical trials seek to resolve inflammation-related issues in conditions such as…

FridayOct 23, 2020 12:05 pm

QualityStocksNewsBreaks – KBL Merger Corp. IV’s (NASDAQ: KBLM) Special Meeting to be Held November 5, 2020, 180 Life Sciences Featured in Exclusive Broadcast

KBL Merger Corp. (NASDAQ, KBLMKBL, KBLMR, KBLMW) (“KBL”), a special purpose acquisition company (“SPAC”) that previously announced the agreement to acquire 180 Life Sciences Corp., today announced postponement of the special meeting of its stockholders (the “Special Meeting”) to November 5, 2020. KBL determined to postpone the Special Meeting (originally scheduled for Monday, October 26, 2020) so that it better aligns with anticipated timing of the proposed business combination with 180 Life Sciences. As a result of this change, the Special Meeting will now be held at 10:00 a.m., local time, on November 5, 2020, at the offices of KBL…

WednesdayOct 21, 2020 11:46 am

QualityStocksNewsBreaks – 180 Life Sciences Corp. Featured in NNW Editorial Discussing Big Pharma Acquisitions

180 Life Sciences Corp. was discussed prominently in an editorial published by NetworkNewsWire (“NNW”), one of 50-plus brands in the InvestorBrandNetwork (“IBN”). The editorial, titled “Banking on the Next Blockbuster Drug,” discusses the significant amounts of time and money being invested by big pharma companies in the pursuit of new drugs, especially those that offer the potential to become blockbuster drugs. A blockbuster drug, or one that generates more than $1 billion in annual sales, can provide enormous benefits for the company that owns and manufactures it. Therefore, large companies operating in the pharmaceutical space commonly acquire promising new drugs — and…

FridayOct 16, 2020 10:57 am

180 Life Sciences Corp. Expands IP Portfolio with EU, U.S., and Chinese Patents

The company’s patent portfolio includes its own intellectual property and exclusive worldwide licenses, including in the U.S., Canada, Europe, Australia, Hong Kong, and China 180 Life Sciences is in the final stages of its merger process with KBL Merger Corp. IV, with the resulting entity to list on NASDAQ under the ticker “ATNF” The company is devoting its clinical-stage biotechnology research to producing solutions that will help battle inflammation. Its primary focus is to treat fibrosis and inflammation using anti-TNF therapy The estimated annual market size for anti-inflammatory therapeutics is projected to grow to an estimated $106.1 billion in 2020.…

WednesdayOct 14, 2020 12:33 pm

180 Life Sciences Corp. Bringing Hope to Those Afflicted by Dupuytren’s Disease and Other Inflammatory Conditions

180 Life Sciences is a clinical-stage biotechnology company developing anti-tumor necrosis factor (“TNF”) therapies to treat a variety of inflammatory conditions. Phase 2b/3 clinical trials on fibrosis and inflammation-causing TNF irregularity are currently underway with first results expected in 2021 The company is to be acquired by a SPAC (NASDAQ: KBLM) (NASDAQ: KBLMR) (NASDAQ: KBLMW) and will be listed on the Nasdaq Capital Market under ticker symbol ATNF Pioneering biotech company, 180 Life Sciences Corp. is bringing hope to sufferers of Dupuytren’s Disease and other inflammatory conditions caused by an impaired immune system. Currently, the company has three major programs…

MondayOct 05, 2020 2:00 pm

QualityStocksNewsBreaks – 180 Life Sciences Corp. Announces New Board Appointments

KBL Merger Corp. (NASDAQ: KBLM) (KBL Merger Corp. Rights NASDAQ: KBLMR) (KBL Merger Corp. Warrant NASDAQ: KBLMW), a Special Purpose Acquisition Corporation (SPAC) that previously entered a definitive agreement to acquire 180 Life Sciences, a clinical-stage biotechnology company, recently announced the appointment of Professor Richard Barker, Larry Gold Md., Shoshana Shendelman PhD., and Donald McGovern Jr. to its board of directors, upon completion of the business combination. 180 Life Sciences is led by Dr. James Woody, who previously served as the founding CEO of OncoMed Pharmaceuticals and president and general manager of Roche Bioscience. “I’m pleased to welcome Richard, Larry,…

FridayOct 02, 2020 12:46 pm

QualityStocksNewsBreaks – 180 Life Sciences Corp. Setting the Stage for Success in Bringing Novel Products to Market

180 Life Sciences, a clinical-stage biotechnology company, is focused on research to solve one of the world’s most significant drivers of disease – inflammation. The company currently has three programs for the development of novel drugs in the areas of fibrosis and anti-TNF, inflammatory pain and ulcerative colitis in ex-smokers. A recent article discusses the company’s strategy to expedite the path to market. The piece reads, “180 Life Sciences has mitigated the risks of its drug development through multiple programs at various stages of development. The company is actively decreasing costs and expediting the time to market by using grant…

FridaySep 25, 2020 11:48 am

180 Life Sciences Corp. Leading Research into Novel Drug Therapies Expected to Produce First Results of Phase 2b/3 Trial in 2021

Anti-inflammatory therapeutics market to generate revenues of $191.42 billion through 2027 Novel drug therapy for Fibrosis and Anti-TNF trials being conducted by Professor Sir Marc Feldmann, who already developed one of the most commonly used anti-TNF medications, Remicade The number of conditions with chronic inflammation is expected to increase persistently over the next 30 years in the United States. 180 Life Sciences is in the process of being acquired by KBLM Merger Corp. and the acquisition is expected to finalize in Q4 2020 Clinical-stage biotechnology company 180 Life Sciences Corp. is leading the way with research into the world’s most…

MondaySep 21, 2020 1:49 pm

KBL Merger Corp. IV (NASDAQ: KBLM) (NASDAQ: KBLMR) (NASDAQ: KBLMW) Fulfilling IPO Goal Through Merger With 180 Life Sciences Corp.

KBL Merger Corp. IV is set to finalize the acquisition of 180 Life Sciences Corp. during Q4 2020 180 Life Sciences Corp. has several ongoing programs at different stages of development, with the leading candidate in Phase 2b/3, helping mitigate the risks involved with its drug development The merger with 180 Life Sciences will enable KBL Merger Corp. IV to enter a market expected to double in size by 2027 180 Life Sciences is growing its patent portfolio through several preclinical studies beginning in two additional areas of inflammatory novel drug studies KBL Merger Corp. (NASDAQ: KBLM) (KBL Merger Corp.…

Site Search

Company Search

Tag: KBL Merger Corp. IV KBLM